Genmab lifts guidance as Darzalex shows new promise

Genmab A/S (CSE:GEN) raised full-year 2016 guidance as it reported 3Q16 earnings that beat estimates, with a boost from royalty and milestone revenue related to multiple myeloma drug Darzalex daratumumab. New data from a Phase Ib study also showed that a subcutaneous formulation of the drug led to serum trough concentrations that were at least comparable to its marketed IV counterpart, suggesting a more convenient dosing option may be on the way.

Buoyed by the news, Genmab gained DKK122 (11%) to DKK1,189 on Thursday...